YELP is higher adding to its year-over-year gain of more than 300%. BofA-Merrill Lynch sees triple-digit territory on the horizon for the shares, initiating coverage with a $100 price target and a “neutral” rating this morning. Despite the equity’s impressive performance on the charts, pessimism prevails on Wall Street. The stock’s Schaeffer’s put/call open interest ratio (SOIR) of 0.94 stands just 10 percentage points from an annual peak, implying that near-term option traders are more put-skewed than usual right now. Plus, the consensus 12-month price target on Yelp Inc (NYSE:YELP) sits at $87.76, representing a discount to the stock’s current perch. Yelp Inc (NYSE:YELP) stock opened today at $86.69 and is currently trading at $85.20. The stock showed a neagtive weekly performance of -3.50%.
Twitter Inc (NYSE:TWTR)’s website has been blocked in Turkey. The ban on the social networking site came just hours after Turkish prime minister Recep Tayyip Erdogan threatened to eradicate Twitter. “We will wipe out all of these,” he proclaimed Thursday. Now anyone trying to access the microblogging service in Turkey is directed to another website that lists three court rulings as reasons for the ban. Twitter Inc (NYSE:TWTR) stock opened at $50.24, in current trading session and currently is at $49.75, by loosing -0.74%.The 52 week range of $38.80-$74.73.Company’s market capitalization is $29.35 billion.
United Technologies (NYSE:UTX) was upgraded by Goldman Sachs from a “neutral” rating to a “buy” rating in a research note issued on Friday, ARN reports. The firm currently has a $138.00 price objective on the stock, up from their previous price objective of $123.00. Goldman Sachs’ price target would indicate a potential upside of 20.22% from the company’s current price. United Technologies Corporation (NYSE:UTX) stock is currently trading at $115.84.The EPS of the stock is 6.21. Company’s market capitalization is $106.15 billion.
Drug makerInterMune Inc. (NASDAQ:ITMN) enjoyed an influx of market activity on its stock after releasing positive trial news on its drug aimed at treating lung cancer. February 25, 2014 was the day that the company’s market valuation more than doubled at the back of the positive news on Pirfenidone. The news caused a market frenzy as analysts fluxed to buy the stock awaiting to see if the drug which is currently being used in Canada and Europe would get the approval by FDA. InterMune Inc (NASDAQ:ITMN) stock opened the session at $37.26, and now is at $36.27. The 52 week range of the ITMN stock remained $8.61-$38.73 and the day range was $35.61-$38.29.
Leave a Reply